09:10 AM EST, 11/17/2025 (MT Newswires) -- Tonix Pharmaceuticals ( TNXP ) said Monday that it has commercially launched Tonmya, a first-in-class treatment for fibromyalgia in adults as a non-opioid analgesic, in the US.

Tonmya's approval by the US Food and Drug Administration was based on two late-stage clinical trials of nearly 1,000 patients in total that evaluated it as a bedtime treatment for fibromyalgia, where findings showed that it significantly reduced daily pain scores compared to placebo at 14 weeks, the company said.